- Advertisement -

AI In Silico Multi-Omics Technique Cuts Therapeutic Development Costs

Bringing a drug from discovery through clinical trials takes too long and is too expensive, with preclinical costs alone estimated at $15 to $100...

AAV Based Gene Therapy for Rare Genetic Disorders: Strategies and Challenges

Broadcast Date: January 19, 2020Time: 8:00 am PT, 11:00 am ET, 17:00 CET REGISTER NOW There are over 7000 rare diseases worldwide, and unfortunately,...

Scientists elaborated the design and application prospect of China’s Tiangong space station

As a manned spacecraft operating in orbit for a long time, a space station embodies a country’s scientific and technological strength comprehensively. China’s manned...

Engineered AAV Vectors Cross Blood-Brain Barrier in Monkeys

Delivery of genetic cargo to specific cells is one of the big challenges facing the gene therapy field. A particular challenge is delivery to...

Sana Biotechnology to Present at the BofA Securities 2021 – GlobeNewswire

SEATTLE, May 04, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today...

HarvestHub app tackles supply chain, food insecurity issues

The COVID-19 pandemic infiltrated almost every aspect of society and life in 2020, even in ways people wouldn’t have immediately expected. Stores that typically...

Enabling In Vivo Lentiviral Therapies: Manufacturing Strategies to Improve Purity, Scalability,...

Lentiviral vectors are gaining momentum not just as ex vivo tools but as potential in vivo therapeutic platforms. But with that shift comes a...

Regenerative Medicine: Promise, Hype, and What Actually Works

From stem cells to platelet-rich plasma, regenerative medicine is often positioned as the future of healthcare. But not all approaches deliver on that promise....

Enabling In Vivo Lentiviral Therapies: Manufacturing Strategies to Improve Purity, Scalability, and Clinical Readiness

Lentiviral vectors are gaining momentum not just as ex vivo tools but as potential in vivo therapeutic platforms. But with that shift comes a...

Regenerative Medicine: Promise, Hype, and What Actually Works

From stem cells to platelet-rich plasma, regenerative medicine is often positioned as the future of healthcare. But not all approaches deliver on that promise....

Global experts highlight new strategies to target human aging

A new meeting report was published in Volume 18 of Aging-US on April 6, 2026, titled "Toward actionable interventions in human aging (12th ARDD meeting, 2025)." The...

more new items

Enabling In Vivo Lentiviral Therapies: Manufacturing Strategies to Improve Purity, Scalability,...

Lentiviral vectors are gaining momentum not just as ex vivo tools but as potential in vivo therapeutic platforms. But with that shift comes a...

Regenerative Medicine: Promise, Hype, and What Actually Works

From stem cells to platelet-rich plasma, regenerative medicine is often positioned as the future of healthcare. But not all approaches deliver on that promise....

Global experts highlight new strategies to target human aging

A new meeting report was published in Volume 18 of Aging-US on April 6, 2026, titled "Toward actionable interventions in human aging (12th ARDD meeting, 2025)." The...